Core Laboratories Resultados de beneficios anteriores
Pasado controles de criterios 3/6
Core Laboratories ha aumentado sus beneficios a una tasa media anual de 8.7%, mientras que los beneficios de la industria de Energy Services han experimentado un crecimiento de 46.2% anual. Los ingresos han ido creciendo a una tasa media de 3.2% al año. La rentabilidad financiera de Core Laboratories es de 10.7%, y sus márgenes netos son de 5.5%.
Información clave
8.66%
Tasa de crecimiento de los beneficios
8.08%
Tasa de crecimiento del BPA
| Crecimiento de la industria Energy Services | 23.71% |
| Tasa de crecimiento de los ingresos | 3.16% |
| Rentabilidad financiera | 10.75% |
| Margen neto | 5.53% |
| Última actualización de beneficios | 31 Mar 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
CLB: Fair Outlook Balances Middle East Disruptions And Governance Changes
Analysts have raised their price target on Core Laboratories from about $14.00 to roughly $16.33, citing updated views on fair value, discount rate, revenue growth, profit margins, and future P/E assumptions. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000 and EPS, ex items, of US$0.05 to US$0.07 for the period (Key Developments).
CLB: Fair Value View Will Rely On Middle East Risk And P/E Assumptions
Analysts have raised their price target on Core Laboratories from $18 to $22, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple as key drivers of the change. What's in the News Core Laboratories revised its first quarter 2026 earnings guidance, citing client driven project delays, travel constraints, and supply chain disruptions linked to geopolitical conflict in the Middle East, and now expects revenue of US$119,000,000 to US$123,000,000, operating income ex items of US$5,700,000 to US$7,100,000, and Earnings Per Share ex items of US$0.05 to US$0.07 (Key Developments).Core Laboratories: Profit Margins Are Too Small To Get Excited About
Summary Core Laboratories remains a HOLD due to persistently low profit margins and unattractive free cash flow yields. Recent Middle East disruptions have significantly impacted CLB’s higher-margin Reservoir Description segment, prompting a downward revision of Q1 EPS guidance. CLB’s capital allocation will continue with a 50/50 split between debt reduction and shareholder returns, targeting leverage below 1.0x. The current valuation at 14x EBITDA is not justified given flat revenues, low margins, and increased operational risks. The stock is valued at low single digit free cash flow yields. Read the full article on Seeking AlphaCLB: Fair Value View Will Rely On Stable Margins And P/E Assumptions
Analysts held their price target on Core Laboratories steady at US$18.00, citing only small tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their overall view of the company. Valuation Changes Fair Value: Held steady at US$18.00, indicating no change in the core valuation output.CLB: Fair Value View Will Rely On Stabilizing Margins And EPS
Analysts kept their Core Laboratories fair value estimate around $18.00. The updated price target mainly reflects slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E rather than a major shift in their view of the stock.CLB: Future Earnings And Margins Are Expected To Gradually Stabilize
Analysts have modestly reduced their price target on Core Laboratories by 1 dollar to 18 dollars. This reflects a slightly lower fair value despite improved expectations for revenue growth, profit margin, and a less demanding future price to earnings multiple.A Look At The Fair Value Of Core Laboratories Inc. (NYSE:CLB)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$14.45 Core...Middle East And Asia Pacific Markets Will Secure Energy Success
With both the discount rate and future P/E ratio remaining essentially stable, the consensus analyst price target for Core Laboratories was unchanged at $14.00. What's in the News Core Laboratories issued third quarter 2025 guidance, expecting revenue of $127.5–134.5 million, operating income of $13.6–16.2 million, operating margin of approximately 11%, and EPS of $0.18–0.22.Core Laboratories Inc.'s (NYSE:CLB) 25% Jump Shows Its Popularity With Investors
Core Laboratories Inc. ( NYSE:CLB ) shareholders would be excited to see that the share price has had a great month...We Think Core Laboratories (NYSE:CLB) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Core Laboratories (NYSE:CLB) Will Be Hoping To Turn Its Returns On Capital Around
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...Is There An Opportunity With Core Laboratories Inc.'s (NYSE:CLB) 49% Undervaluation?
Key Insights The projected fair value for Core Laboratories is US$23.89 based on 2 Stage Free Cash Flow to Equity Core...Core Laboratories Inc.'s (NYSE:CLB) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 20x Core Laboratories Inc. ( NYSE:CLB ) may be sending bearish signals at...Is Core Laboratories Inc. (NYSE:CLB) Trading At A 27% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Core Laboratories fair value estimate is US$27.00 Core...Core Laboratories Inc. (NYSE:CLB) Not Lagging Market On Growth Or Pricing
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...Returns On Capital At Core Laboratories (NYSE:CLB) Paint A Concerning Picture
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Is Core Laboratories (NYSE:CLB) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Product Launches And Deleveraging To Propel Growth Amidst Geopolitical Challenges
Diversification in geographical markets and services strengthens revenue by expanding market presence and targeting regions with growing demand.Is Core Laboratories Inc. (NYSE:CLB) Trading At A 38% Discount?
Key Insights The projected fair value for Core Laboratories is US$29.58 based on 2 Stage Free Cash Flow to Equity...What You Can Learn From Core Laboratories Inc.'s (NYSE:CLB) P/E
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...These Return Metrics Don't Make Core Laboratories (NYSE:CLB) Look Too Strong
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...It's Unlikely That Core Laboratories Inc.'s (NYSE:CLB) CEO Will See A Huge Pay Rise This Year
Key Insights Core Laboratories' Annual General Meeting to take place on 8th of May Salary of US$886.9k is part of CEO...Is Core Laboratories Inc. (NYSE:CLB) Trading At A 25% Discount?
Key Insights The projected fair value for Core Laboratories is US$22.93 based on 2 Stage Free Cash Flow to Equity Core...Why We're Not Concerned About Core Laboratories Inc.'s (NYSE:CLB) Share Price
Core Laboratories Inc.'s ( NYSE:CLB ) price-to-earnings (or "P/E") ratio of 19.8x might make it look like a sell right...Desglose de ingresos y gastos
Cómo gana y gasta dinero Core Laboratories. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 26 | 525 | 29 | 45 | 0 |
| 31 Dec 25 | 527 | 30 | 44 | 0 |
| 30 Sep 25 | 518 | 32 | 43 | 0 |
| 30 Jun 25 | 517 | 30 | 41 | 0 |
| 31 Mar 25 | 518 | 28 | 40 | 0 |
| 31 Dec 24 | 524 | 31 | 39 | 0 |
| 30 Sep 24 | 523 | 26 | 38 | 0 |
| 30 Jun 24 | 514 | 24 | 39 | 0 |
| 31 Mar 24 | 511 | 38 | 34 | 0 |
| 31 Dec 23 | 510 | 37 | 39 | 0 |
| 30 Sep 23 | 509 | 41 | 39 | 0 |
| 30 Jun 23 | 510 | 39 | 40 | 0 |
| 31 Mar 23 | 503 | 24 | 41 | 0 |
| 31 Dec 22 | 490 | 19 | 38 | 0 |
| 30 Sep 22 | 487 | 15 | 40 | 0 |
| 30 Jun 22 | 479 | 9 | 45 | 0 |
| 31 Mar 22 | 477 | 10 | 48 | 0 |
| 31 Dec 21 | 470 | 20 | 44 | 0 |
| 30 Sep 21 | 459 | 31 | 28 | 0 |
| 30 Jun 21 | 446 | 33 | 22 | 0 |
| 31 Mar 21 | 443 | 19 | 21 | 0 |
| 31 Dec 20 | 487 | -97 | 33 | 0 |
| 30 Sep 20 | 530 | -101 | 47 | 0 |
| 30 Jun 20 | 598 | -80 | 50 | 0 |
| 31 Mar 20 | 651 | -55 | 50 | 0 |
| 31 Dec 19 | 668 | 94 | 47 | 0 |
| 30 Sep 19 | 685 | 92 | 63 | 0 |
| 30 Jun 19 | 694 | 90 | 65 | 0 |
| 31 Mar 19 | 700 | 96 | 68 | 0 |
| 31 Dec 18 | 701 | 80 | 63 | 0 |
| 30 Sep 18 | 698 | 93 | 50 | 0 |
| 30 Jun 18 | 678 | 91 | 48 | 0 |
| 31 Mar 18 | 661 | 87 | 47 | 0 |
| 31 Dec 17 | 648 | 81 | 48 | 0 |
| 30 Sep 17 | 627 | 75 | 45 | 0 |
| 30 Jun 17 | 608 | 71 | 41 | 0 |
| 31 Mar 17 | 598 | 67 | 41 | 0 |
| 31 Dec 16 | 590 | 65 | 39 | 0 |
| 30 Sep 16 | 628 | 64 | 43 | 0 |
| 30 Jun 16 | 682 | 81 | 47 | 0 |
| 31 Mar 16 | 738 | 99 | 48 | 0 |
| 31 Dec 15 | 798 | 115 | 50 | 0 |
| 30 Sep 15 | 893 | 166 | 49 | 0 |
| 30 Jun 15 | 972 | 199 | 49 | 0 |
Ingresos de calidad: CLB tiene una única gran ganancia de $9.5M que afecta a sus resultados financieros de los últimos 12 meses de 31st March, 2026.
Margen de beneficios creciente: Los actuales márgenes de beneficio (5.5%) de CLB son superiores a los del año pasado (5.4%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de CLB han crecido un 8.7% al año en los últimos 5 años.
Acelerando crecimiento: El crecimiento de los beneficios de CLB en el último año (3.6%) está por debajo de su media de 5 años (8.7% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de CLB en el último año (3.6%) superó al de la industria Energy Services -33%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de CLB (10.7%) se considera baja.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/07 16:28 |
| Precio de las acciones al final del día | 2026/05/07 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Core Laboratories Inc. está cubierta por 30 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| James West | Barclays |
| Nicholas Green | Bernstein |
| Saurabh Pant | BofA Global Research |